The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Analysis of prognostic factors in ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital studies
Abstract
BACKGROUND.: Advances in systemic and local therapies have improved outcomes for patients with the Ewing sarcoma family of tumors (ESFT). As new treatments are developed, a critical review of data from past treatment eras is needed to identify clinically relevant risk groups. METHODS.: The authors reviewed the records of 220 patients with ESFT who were treated on protocols at St. Jude Children's Research Hospital from 1979 to 2004. Two treatment eras were defined. Factors predictive of outcome were analyzed to identify distinct risk groups. RESULTS.: The median age at diagnosis was 13.7 years (range, 1.1–25.2 years). Metastatic disease was associated with tumors measuring >8 cm (P = .002) and axial location (P = .014). The 5‐year overall survival (OS) estimate (63.5% ± 3.5%) did not appear to differ by protocol. Tumor stage and size were found to be the only independent predictors of outcome. Treatment era and type of local control therapy were found to influence the outcome of patients with localized disease. Four risk groups were defined: favorable risk (age <14 years with localized, nonpelvic tumors), intermediate risk (localized, age ≥14 years, or pelvic tumors), unfavorable‐pulmonary (isolated lung metastases), and unfavorable‐extrapulmonary (extrapulmonary metastases). The 5‐year OS estimates for these groups were 88.1% ± 4.4%, 64.9% ± 5.2%, 53.8% ± 9.4%, and 27.2% ± 7.3%, respectively (P < .001). The incidence of therapy‐related leukemia was significantly higher during the second treatment era, when more intensified regimens were used (6.1% ± 2.7% vs 0% ± 0%; P = .005). CONCLUSIONS.: Risk stratification schemes such as this should be used to prospectively evaluate novel risk‐based therapies. Studies of biologic pathways may help to refine this model. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miser, J. S., Kinsella, T. J., Triche, T. J., Tsokos, M., Jarosinski, P., Forquer, R., Wesley, R., & Magrath, I. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1191 · Cited by 317
Cited by
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines.
Lewin, J., Puri, A., Quek, R., Ngan, R., Alcasabas, A. P., Wood, D., & Thomas, D. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70475-3 · Cited by 44
Metadata
- Authors
- Rodríguez‐Galindo, C., Liu, T., Krasin, M. J., Wu, J., Billups, C. A., Daw, N. C., Spunt, S. L., Rao, B. N., Santana, V. M., & Navid, F.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-06-29
- Volume
- 110
- Issue
- 2
- Pages
- 375-384
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1577757154
- Cited by
- 239
- References
- 1
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.